SavedAdd your journal

Journals / Bakırköy Tıp Dergisi / 2014 / Cilt: 10 - Sayı: 2

Hemodi yalize giren son dönem böbrek hastalığı olan hipertiroidili bir olguda radyoaktif i yot ile tedavi: Olgu sunumu

Radioiodine Therapy for Hyperthyroidism in a Patient with End-Stage Renal Disease on Hemodialysis: Case Report

Müge TAMAM
Mehmet MÜLAZIMOĞLU
Nurcan EDİS
Ercan UYANIK
Tevfik ÖZPAÇA
Pages
75–77
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present an ESRD patient with hyperthyroidism who is receiving hemodialysis treated with radioiodine therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Toxic nodular goiter is a rare entity in end-stage renal disaese (ESRD) patients.
📊
Key Findings & Data:In ESRD patients, hypothyroidism is generally seen, whereas hyperthyroidism is rare.
💡
Conclusion & Impact:We present an ESRD patient with hyperthyroidism who is receiving hemodialysis treated with radioiodine therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Toxic nodular goiter is a rare entity in end-stage renal disaese (ESRD) patients. In ESRD patients, hypothyroidism is generally seen, whereas hyperthyroidism is rare. Treatment with radioactive iodine (RAI) may be necessary for hyperthyroidism in patients with end-stage renal disease who require haemodialysis. Because RAI is cleared mainly by the kidneys in patients with normal renal function, many problems may (issues) arise in patients who are on hemodialysis but require RAI treatment. We present an ESRD patient with hyperthyroidism who is receiving hemodialysis treated with radioiodine therapy.

Özet

Toksik nodüler guatr son dönem böbrek yetmezliği hastalığında nadir görülen bir durumdur. Son dönem böbrek yetmezliği olan hastalarda, genellikle hipotiroidizm görülürken hipertiroidi nadirdir. Hemodiyaliz ile tedavi edilen son dönem böbrek hastalığı olan hipertiroidi hastalarında radyoaktif iyot (RAI) tedavisi gerekli olabilir. RAI, özellikle böbrek fonksiyonu normal olan hastalarda böbrekler tarafından temizlendiğinden, hemodiyaliz hastası olup RAI tedavisi alanlarda çeşitli problemler ortaya çıkabilmektedir. Hipertiroidi hastalığı radyoaktif iyot tedavisi ile tedavi edilen ve hemodiyalize giren son dönem böbrek yetmezliği hastası sunulmuştur

🔖

Cite This Article

TAMAM, M., MÜLAZIMOĞLU, M., EDİS, N., UYANIK, E., ÖZPAÇA, T. (2014). Hemodi yalize giren son dönem böbrek hastalığı olan hipertiroidili bir olguda radyoaktif i yot ile tedavi: Olgu sunumu. Bakırköy Tıp Dergisi, Cilt: 10 - Sayı: 2, 75–77. https://ajindex.com/articles/129056

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lim VS. Thyroid function in patients with chronic renal failure. Am J Kidney Dis 2001; 38: S80-84
  2. Demko TM, Tulchinsky M, Miller KL, Cheung JY, Groff JA. Diagnosis and radioablation treatment of toxic multinodular goiter in a hemodialysis patient (abstract). Am J Kidney Dis 1998; 31: 698-700
  3. Homer L, Smith AH. Radiation protection issues of treating hyperthyroidism with 131 I in patients on haemodialysis. Nucl Med Commun. 2002; 23: 261-264
  4. Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab 2000; 85: 3058-3064
  5. Sinsakul M, Ali A. Radioactive 131I use in end-stage renal disease: nightmare or nuisance? Semin Dial 2004; 17: 53-56
  6. Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005; 15: 1321- 1331
  7. Alevizaki C, Molfetas M, Samartzis A, Vlassopoulou B, Vassilopoulos C, Rondogianni P, Kottou S, et al. Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations. Hormones 2006; 5: 276-287
  8. Toubert ME, Michel C, Metivier F, Peker MC, Rain JD. Iodine-131 ablation therapy for a patient receiving peritoneal dialysis. Clin Nucl Med 2001; 26: 302-305
  9. Magné N, Magné J, Bracco J, Bussière F. Disposition of radioiodine (131)I therapy for thyroid carcinoma in a patient with severely impaired renal function on chronic dialysis. Jpn J Clin Oncol 2002; 32: 202-205
  10. Meller J, Sahlmann CO, Becker W. Nuclear medicine studies in the dialysis patient. Semin Dial 2002; 15: 269-276
  11. Mello AM, Isaacs R, Petersen J, Kronenberger S, McDougall IR. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis. Clin Nucl Med 1994; 19: 776-781
  12. Jiménez RG, Moreno AS, Gonzalez EN, et al. Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method. Thyroid 2001; 11: 1031- 1034
  13. Wang TH, Lee CH, Tseng LM, Liu RH. The management of well-differentiated thyroid cancer with end-stage renal disease. Endocrine 2003; 21: 227-231.